This established a circulating malignancy at a median time of 21 days after injection, accumulating a B220lowCd19+Cd5+ CLL-like population in the blood of all recipients (n = 7 mice; Supplemental Fig. 6C). The gene discussed is CD5; the disease is B-cell chronic lymphocytic leukemia.